PMID- 25876156
OWN - NLM
STAT- MEDLINE
DCOM- 20160222
LR  - 20191008
IS  - 1433-7339 (Electronic)
IS  - 0941-4355 (Print)
IS  - 0941-4355 (Linking)
VI  - 23
IP  - 8
DP  - 2015 Aug
TI  - Nasal vestibulitis due to targeted therapies in cancer patients.
PG  - 2391-8
LID - 10.1007/s00520-014-2580-x [doi]
AB  - BACKGROUND AND PURPOSE: Cancer patients treated with targeted therapies (e.g., 
      epidermal growth factor receptor inhibitors) are susceptible to dermatologic 
      adverse events (AEs) including secondary skin infections. Whereas infections such 
      as paronychia and cellulitis have been reported, nasal vestibulitis (NV) has not 
      been described with the use of these agents. The aim of our study was to 
      characterize NV in cancer patients treated with targeted therapies. METHODS: We 
      utilized a retrospective chart review of cancer patients who had been referred to 
      dermatology and were diagnosed with NV. We recorded data including demographics, 
      referral reason, underlying malignancy, targeted anticancer regimen, NV 
      treatment, and nasal bacterial culture results. RESULTS: One Hundred Fifteen 
      patients were included in the analysis, of which 13 % experienced multiple NV 
      episodes. Skin rash was the most common reason (90 %) for a dermatology referral. 
      The most common underlying malignancies were lung (43 %), breast (19 %), and 
      colorectal (10 %) cancer. Sixty-eight percent of patients had been treated with 
      an EGFRI-based regimen. Nasal cultures were obtained in 60 % of episodes, of 
      which 94 % were positive for one or more organisms. Staphylococcus aureus was the 
      most commonly isolated organism [methicillin-sensitive S. aureus 43 %; 
      methicillin-resistant S. aureus 3 %]. CONCLUSIONS: We report the incidence and 
      characteristics of an unreported, yet frequent dermatologic condition in cancer 
      patients treated with targeted therapies. These findings provide the basis for 
      additional studies to describe the incidence, treatment, and consequences of this 
      event. A better understanding of NV would mitigate its impact on patients' 
      quality of life and risk for additional dermatologic AEs.
FAU - Ruiz, Janelle N
AU  - Ruiz JN
AD  - Dermatology Service, Memorial Sloan Kettering Cancer Center, 60th Street 
      Outpatient Center, Suite 407, Room 4312, 16 East 60th St., New York, NY, 10022, 
      USA.
FAU - Belum, Viswanath Reddy
AU  - Belum VR
FAU - Boers-Doets, Christine B
AU  - Boers-Doets CB
FAU - Kamboj, Mini
AU  - Kamboj M
FAU - Babady, N Esther
AU  - Babady NE
FAU - Tang, Yi-Wei
AU  - Tang YW
FAU - Valdez, Tulio A
AU  - Valdez TA
FAU - Lacouture, Mario E
AU  - Lacouture ME
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - R25 CA020449/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20150122
PL  - Germany
TA  - Support Care Cancer
JT  - Supportive care in cancer : official journal of the Multinational Association of 
      Supportive Care in Cancer
JID - 9302957
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Methicillin-Resistant Staphylococcus aureus/*metabolism
MH  - Middle Aged
MH  - Molecular Targeted Therapy/adverse effects
MH  - Nasal Mucosa/*microbiology
MH  - Neoplasms/*complications/drug therapy
MH  - Nose Diseases/*microbiology
MH  - Quality of Life
MH  - Retrospective Studies
MH  - Rhinitis/*etiology
MH  - Skin Diseases/*etiology
MH  - Staphylococcal Infections/*etiology/microbiology
MH  - Staphylococcus aureus
MH  - Young Adult
PMC - PMC4536911
MID - NIHMS707722
COIS- Conflicts of interest JNR, VRB, MK, NEB, YT, and TV have nothing to disclose. 
      CBB-D has a speaking, consultant, or advisory role with Amgen, AstraZeneca, Bayer 
      Pharmaceuticals, Boehringer Ingelheim, Eusa Pharma, GlaxoSmithKline, Merck 
      Serono, Merck Sharp and Dohme, Novartis, Pfizer, and Roche. MEL has a speaking, 
      consultant or advisory role with Advancell, Amgen, AstraZeneca, Augmentium, Aveo, 
      Bayer, Berg Pharma, Biopharm Communications, Boehringer Ingelheim, Brickell 
      Biotech, Bristol-Myers Squibb, Clinical Assistance Programs, Clinical Care 
      Options, EMD Serono, Envision Communications, Foamix, Galderma, Genentech, 
      GlaxoSmithKline, Helsinn, Institute for Medical Education and Research, 
      Integro-MC, Lindi Skin, Medscape, Medtrend International, Merck, Nerre 
      Therapeutics, Novartis, Novocure, Oncology Specialty Group, OSI Pharmaceuticals, 
      Permanyer, Physicians Education Resource, Pierre Fabre, Pfizer, Reata 
      Pharmaceuticals, Roche, Sandoz, Sanofi Aventis, and Threshold Pharmaceuticals.
EDAT- 2015/04/16 06:00
MHDA- 2016/02/24 06:00
PMCR- 2016/08/01
CRDT- 2015/04/16 06:00
PHST- 2014/08/09 00:00 [received]
PHST- 2014/12/18 00:00 [accepted]
PHST- 2015/04/16 06:00 [entrez]
PHST- 2015/04/16 06:00 [pubmed]
PHST- 2016/02/24 06:00 [medline]
PHST- 2016/08/01 00:00 [pmc-release]
AID - 10.1007/s00520-014-2580-x [doi]
PST - ppublish
SO  - Support Care Cancer. 2015 Aug;23(8):2391-8. doi: 10.1007/s00520-014-2580-x. Epub 
      2015 Jan 22.